Dostarlimab, a humanized monoclonal PD-1 blocking antibody, is being tested as a cancer therapy in this review. Specifically, it addresses mismatch repair failure in endometrial cancer and locally progressed rectal cancer patients.
Data Sources
A thorough database search found Dostarlimab clinical trials and studies. Published publications and ongoing clinical trials on Dostarlimab's efficacy as a single therapy and in conjunction with other medicines across cancer types were searched.
Data Summary
The review recommends Dostarlimab for endometrial cancer mismatch repair failure, as supported by GARNET studies. The analysis also highlights locally advanced rectal cancer findings. In the evolving area of cancer therapy, immune checkpoint inhibitors including pembrolizumab, avelumab, atezolizumab, nivolumab, and durvalumab were discussed.
Conclusions
Locally advanced rectal cancer patients responded 100% to Dostarlimab. Many clinical trials, including ROSCAN, AMBER, IOLite, CITRINO, JASPER, OPAL, PRIME, PERLA, and others, are investigating Dostarlimab in combination treatment. This research sheds light on Dostarlimab's current and future possibilities, in improving cancer immunotherapy understanding.
SatyanarayanaU. Biochemistry-E-book. India: Elsevier Health Sciences, 2017.
2.
SiegelRLMillerKDFuchsHE, et al.Cancer statistics, 2022. CA Cancer J Clin2022; 72: 7–33.
3.
BrayFFerlayJSoerjomataramI, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018; 68: 394–424.
4.
TrichopoulosDLiFPHunterDJ. What causes cancer?Sci Am1996; 275: 80–87.
5.
DemariaMO'LearyMNChangJ, et al.Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov2017; 7: 165–176.
6.
NisticòCPagliariFChiarellaE, et al.Lipid droplet biosynthesis impairment through DGAT2 inhibition sensitizes MCF7 breast cancer cells to radiation. Int J Mol Sci2021; 22: 10102.
7.
CharlotMSteinJNDamoneE, et al.Effect of an antiracism intervention on racial disparities in time to lung cancer surgery. J Clin Oncol2022; 40: 1755–1762.
8.
LinH-MNikolicIYangJ, et al.MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Sci Rep2018; 8: 7820.
9.
TopalianSLHodiFSBrahmerJR, et al.Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med2012; 366: 2443–2454.
10.
EnoJ. Immunotherapy through the years. J Adv Pract Oncol2017; 8: 747.
11.
LacalPMAtzoriMGRuffiniF, et al.Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. Pharmacol Res2020; 159: 104957.
12.
NelHJMalmströmVWraithDC, et al.Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy. Lancet Rheumatol2020; 2: e712–e723.
13.
LuVMShahAHVallejoFA, et al.Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report. Neurosurgical Focus FOC2021; 50: E3.
14.
HaoMHouSLiW, et al.Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Transl Med2020; 12: eaaz6667.
15.
ShaeDBaljonJJWehbeM, et al.Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines. ACS Nano2020; 14: 9904–9916.
16.
NarayanaswamyRTorchilinVP. Targeted delivery of combination therapeutics using monoclonal antibody 2C5-modified immunoliposomes for cancer therapy. Pharm Res2021; 38: 429–450.
17.
PaikJ. Nivolumab plus relatlimab: first approval. Drugs2022; 82: 925–931.
18.
SaungMTPelosofLCasakS, et al.FDA Approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist2021; 26: 797–806.
19.
PoggioMHuTPaiC-C, et al.Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell2019; 177: 414–427.e413.
20.
ChenSZhangZZhengX, et al.Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol2021; 11: 562315.
21.
ZhouYLiH. Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors. Front Neurosci2023; 17: 1227049. 20230629.
22.
ZhangXTChenHShaoW, et al.A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open2021; 7: 1–14.
23.
MarkhamA. Dostarlimab: first approval. Drugs2021; 81: 1213–1219.
24.
OakninAGilbertLTinkerAV, et al.LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from GARNET. Ann Oncol2020; 31: S1166.
25.
DiounSChenLMelamedA, et al.Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: a cost-effectiveness study. BJOG: Int J Obs Gynaecol2023; 130: 214–221.
26.
MorenoVBarretina-GinestaM-PGuoW, et al.Abstract CT053: preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced NSCLC and MSI-H endometrial cancer. Cancer Res2018; 78: CT053–CT053.
27.
HaikalAShamkhIMAhmedA. In silico inhibition of three cancer inducing receptors, IL-6, CTLA-4, and B7-2 by Dostarlimab may explain the 100% complete recovery rate in MMRd locally advanced rectal cancer seen in pivotal ‘immunoablative’ neoadjuvant immunotherapy clinical trial. A Cancer Therapy Breakthrough2022.
28.
HussainHBurneyMHRehanST, et al.Dostarlimab: a breakthrough in the field of oncology. Ann Med Surgery2022; 80: 104046.
29.
OakninAGilbertLTinkerAV, et al.Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer2022; 10: e003777.
30.
LuSBowsherRRClancyA, et al.An integrated analysis of dostarlimab immunogenicity. AAPS J2021; 23: 1–12.
31.
KanaviRSChathamvelliASaikiaD. Dostarlimab for endometrial cancer: a comprehensive review of clinical outcomes. Int J Sci Healthcare Res2023; 8: 136.
JeongT-JLeeH-TGuN, et al.The high-resolution structure reveals remarkable similarity in PD-1 binding of Cemiplimab and Dostarlimab, the FDA-approved antibodies for cancer immunotherapy. Biomedicines2022; 10: 3154.
34.
KumarSGhoshSSharmaG, et al.Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. mAbs2021; 13: 1954136.
35.
SullivanMRUgoliniGSSarkarS, et al.Quantifying the efficacy of checkpoint inhibitors on CD8 + cytotoxic T cells for immunotherapeutic applications via single-cell interaction. Cell Death Dis2020; 11: 979.
36.
KaplonHMuralidharanMSchneiderZ, et al.Antibodies to watch in 2020. mAbs2020; 12: 1703531.
37.
KaplonHChenowethACrescioliS, et al.Antibodies to watch in 2022. In: MAbs. Taylor & Francis, 2022, pp.2014296.
38.
IssafrasHFanSTsengC-L, et al.Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. Plos One2021; 16: e0257972.
39.
ShimizuKSugiuraDOkazakiI-m, et al.PD-1 imposes qualitative control of cellular transcriptomes in response to T cell activation. Mol Cell2020; 77: 937–950.e936.
40.
AlkholifiFKAlsaffarRM. Dostarlimab an inhibitor of PD-1/PD-L1: a new paradigm for the treatment of cancer. Medicina2022; 58: 1572.
41.
MorenoVRodaDPikielJ, et al.Safety and efficacy of Dostarlimab in patients with recurrent/advanced non–small cell lung cancer: results from cohort E of the phase I GARNET trial. Clin Lung Cancer2022; 23: e415–e427.
42.
MusacchioLSalutariVPignataS, et al.Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: nItCHE trial (MITO 33). International J Gynecologic Cancer2021; 31: 1369.
43.
YapTABessudoAHamiltonE, et al.IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer2022; 10: e003924.
44.
PeretsRBarJRascoDW, et al.Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol2021; 32: 395–403.
45.
MotzerRJEscudierBMcDermottDF, et al.Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer2020; 8: e000891.
46.
OakninATinkerAVGilbertL, et al.Clinical activity and safety of the anti–programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol2020; 6: 1766–1772.
47.
VivekMElvisOAyodotunS, et al.Lymphocyte signaling and function in altered physiological environments. In: IstifliESBasri İlaH (eds) Lymphocytes. Rijeka: IntechOpen, 2018, pp.Ch. 2.
48.
TatsuakiT. Signaling pathway for the development of Pre-B cells. In: IstifliESBasri İlaH (eds) Lymphocytes. Rijeka: IntechOpen, 2018, pp.Ch. 3.
49.
MalavikaB. Understanding B lymphocyte development: a long way to go. In: IstifliESBasri İlaH (eds) Lymphocytes. Rijeka: IntechOpen, 2018, pp.Ch. 4.
50.
XiaHWangWCrespoJ, et al.Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity. Sci Immunol2017; 2: eaan4631.
51.
MajTWangWCrespoJ, et al.Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol2017; 18: 1332–1341.
52.
YangSZhangQLiuS, et al.PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. Am J Clin Exp Urol2016; 4: 1–8. 20160128.
53.
OakninADuskaLRSullivanRJ, et al.Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer. Gynecol Oncol2019; 154: 17.
54.
KunduMDasBCTK. A current trend of clinical trials on endometrial cancer in India. World J Clin Case Rep Case Ser2022; 2: 1011.
55.
GolayJManganiniMFacchinettiV, et al.Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica2003; 88: 1002–1012.
56.
AguilarOAFongL-KIshiyamaK, et al.The CD3ζ adaptor structure determines functional differences between human and mouse CD16 Fc receptor signaling. J Exp Med2022; 219: e20220022.
57.
DixonKJWuJWalcheckB. Engineering anti-tumor monoclonal antibodies and fc receptors to enhance ADCC by human NK cells. Cancers2021; 13: 312.
58.
RavetchJVBournazosS. Human IgG Fc domain variants with improved effector function. US Patents, 2019.
59.
RavetchJVBournazosS. Human IgG Fc domain variants with improved effector function. US Patents, 2023.
60.
StrohlWVafaO. Antibody Fc mutants with ablated effector functions. US Patents, 2015.
61.
QiuHMacknessB. Fc variants with enhanced binding to fcrn and prolonged half-life. US Patents, 2019.
62.
YangXLiJGuoE, et al.Preclinical basis of the efficacy and pharmacodynamics of finotonlimab, a humanized anti-PD-1 monoclonal antibody with potent implications for clinical benefit. bioRxiv2023; 2023: 2001. 2016.524197.
63.
HuangJBrameshuberMZengX, et al.A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4+ T cells. Immunity2013; 39: 846–857.
64.
LakenHKehryMMcNeeleyP, et al.Identification and characterization of TSR-042, a novel anti-PD-1 therapeutic antibody. Eur J Cancer2016; 69: S102.
65.
GlatzerMTanderupKRovirosaA, et al.Role of brachytherapy in the postoperative management of endometrial cancer: decision-making analysis among experienced European radiation oncologists. Cancers (Basel)2022; 14: 906.
66.
MartiCDelucheEJochumF, et al.Management of endometrial cancer: French society of onco-gynecology‘s evaluation through a delphi survey. J Clin Med2022; 11: 6765.
67.
Casas-ArozamenaCCortegosoAPiñeiro-PerezR, et al.Improving the management of endometrial cancer patients through the use of liquid biopsy analyses: a case report. Int J Mol Sci2022; 23: 8539.
68.
Dominguez-ValentinMSampsonJRSeppäläTT, et al.Cancer risks by gene, age, and gender in 6350 carriers ofpathogenic mismatch repair variants: findings from the prospective lynch SyndromeDatabase. Genet Med2020; 22: 15–25.
69.
O’maraTAGlubbDMAmantF, et al.Identification of nine new susceptibility loci for endometrial cancer. Nat Commun2018; 9: 3166.
70.
HampelHPearlmanRde la ChapelleA, et al.Double somatic mismatch repair gene pathogenic variants as common as lynch syndrome among endometrial cancer patients. Gynecol Oncol2021; 160: 161–168.
71.
AndreTLonardiSWongM, et al.Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): first report of the full cohort from CheckMate-142. J Clin Oncol2018; 36: 553–553.
72.
RalserDJCondicMKlümperN, et al.Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer. J Cancer Res Clin Oncol2022; 149: 2417–2424.
OakninAGilbertLTinkerA, et al.76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial. Ann Oncol2021; 32: S388–S389.
75.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET), https://clinicaltrials.gov/ct2/show/NCT02715284 (March 22, 2016).
76.
OttPABangY-JBerton-RigaudD, et al.Pembrolizumab in advanced endometrial cancer: preliminary results from the phase ib KEYNOTE-028 study. J Clin Oncol2016; 34: 5581–5581.
77.
O'MalleyDMarabelleADe Jesus-AcostaA, et al.1044P - Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study. Ann Oncol2019; 30: v425–v426.
78.
TamuraKHasegawaKKatsumataN, et al.Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci2019; 110: 2894–2904.
79.
KonstantinopoulosPALuoWLiuJF, et al.Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol2019; 37: 2786–2794.
80.
AntillYCKokPSRobledoK, et al.Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). J Clin Oncol2019; 37: 5501–5501.
81.
KashermanLAhrariSLheureuxS. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol2021; 17: 877–892.
82.
LiuJFGordonMVenerisJ, et al.Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol2019; 154: 314–322.
83.
MakkerVTaylorMHAghajanianC, et al.Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol2020; 38: 2981–2992. 20200313.
WijayaSTNgoiNYLTanDSP. The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers. Best Practice Res Clin Obs Gynaecol2022; 78: 14–35.
MadariagaAGargSTchrakianN, et al.Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. Nat Commun2023; 14: 1452.
Ray-CoquardILLearyABigotF, et al.ROCSAN Trial (GINECO-EN203b/ENGOT-EN8): a multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy. J Clin Oncol2021; 39: TPS5604–TPS5604.
MirzaMRColemanRLHankerLC, et al.ENGOT-EN6/NSGO-RUBY: a phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). J Clin Oncol2020; 38: TPS6107–TPS6107.
92.
MirzaMColemanRHankerL, et al.820TiP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: a phase III, randomized, double-blind, study of dostarlimab+ carboplatin-paclitaxel followed by dostarlimab+ niraparib versus placebo (PBO)+ carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC). Ann Oncol2021; 32: S770–S771.
93.
OttPABangY-JBerton-RigaudD, et al.Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. Obstet Gynecol Surv2018; 73: 26–27.
94.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71: 209–249.
95.
SiegelRLWagleNSCercekA, et al.Colorectal cancer statistics, 2023. CA Cancer J Clin2023; 73: 233–254.
96.
EileenMMelinaAGiniA, et al.Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut2023; 72: 38.
97.
GuoJYuZDasM, et al.Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano2020; 14: 5075–5089.
98.
BullmanSPedamalluCSSicinskaE, et al.Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science2017; 358: 1443–1448.
99.
CercekALumishMSinopoliJ, et al.PD-1 Blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med2022; 386: 2363–2376.
100.
OhCRKimJEHongYS, et al.Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. Int J Cancer2022; 150: 2038–2045.
101.
OvermanMJBergamoFMcDermottRS, et al.Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): long-term survival according to prior line of treatment from CheckMate-142. J Clin Oncol2018; 36: 554–554.
102.
LealADPaludoJFinnesHD, et al.Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). J Clin Oncol2017; 35: 3558–3558.
103.
FelipEAltorkiNZhouC, et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet2021; 398: 1344–1357.
104.
KimJHKimSYBaekJY, et al.A phase II study of avelumab monotherapy in patients with mismatch repair–deficient/microsatellite instability–high or POLE-mutated metastatic or unresectable colorectal cancer. crt2020; 52: 1135–1144.
105.
LarkinJMinorDD'AngeloS, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol2018; 36: 383–390. 20170703.
106.
LongGVAtkinsonVAsciertoPA, et al.Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol2016; 27: 1940–1946.
107.
HodiFSChiarion-SileniVGonzalezR, et al.Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol2018; 19: 1480–1492.
108.
LongGVSchadendorfDVecchioMD, et al.Abstract CT004: adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). Cancer Res2021; 81: CT004–CT004.
109.
ArmandPEngertAYounesA, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol2018; 36: 1428–1439. 20180327.
110.
EscudierBSharmaPMcDermottDF, et al.Checkmate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol2017; 72: 962–971.
111.
LenzH-JVan CutsemELuisa LimonM, et al.First-Line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol2022; 40: 161–170.
112.
PetersSCreelanBHellmannMD, et al.Abstract CT082: impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026. Cancer Res2017; 77: CT082–CT082.
113.
WeberJSD'AngeloSPMinorD, et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol2015; 16: 375–384.
114.
ChenRZinzaniPLLeeHJ, et al.Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood2019; 134: 1144–1153.
115.
PalumboCMazzoneEMistrettaFA, et al.A plea for optimizing selection in current adjuvant immunotherapy trials for high-risk nonmetastatic renal cell carcinoma according to expected cancer-specific mortality. Clin Genitourin Cancer2020; 18: 314–321.e311.
116.
MachielsJ-PTaoYBurtnessB, et al.Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncol2020; 16: 1235–1243.
117.
MachielsJ-PHLicitraLRischinD, et al.KEYNOTE-412: pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). J Clin Oncol2017; 35: TPS6090–TPS6090.
118.
MachielsJTaoYBurtnessB, et al.LBA5 Primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol2022; 33: S1399.
119.
BorghaeiHLangerCJGadgeelS, et al.24-Month Overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non–small cell lung cancer. J Thorac Oncol2019; 14: 124–129.
120.
InsingaRPVannessDJFelicianoJL, et al.Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Curr Med Res Opin2019; 35: 1241–1256.
121.
ShaverdianNLisbergAEBornazyanK, et al.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol2017; 18: 895–903.
122.
HamidORobertCDaudA, et al.Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol2019; 30: 582–588.
123.
GaronEBHellmannMDRizviNA, et al. Five-Year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol2019; 37: 2518–2527. 20190602.
124.
LeighlNBRedmanMWRizviN, et al.Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer2021; 9: e002973.
125.
BorghaeiHRedmanMWKellyK, et al.SWOG S1400a (NCT02154490): a phase II study of durvalumab for patients with previously treated stage IV or recurrent squamous cell lung cancer (lung-MAP sub-study). Clin Lung Cancer2021; 22: 178–186.
126.
RedmanMWPapadimitrakopoulouVAMinichielloK, et al.Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol2020; 21: 1589–1601.
127.
PowlesTvan der HeijdenMSCastellanoD, et al.Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol2020; 21: 1574–1588.
128.
FerraraRMezquitaLTexierM, et al.Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol2018; 4: 1543–1552.
129.
PowlesTO'DonnellPHMassardC, et al.Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol2017; 3: e172411–e172411.
130.
RizviNAChoBCReinmuthN, et al.Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol2020; 6: 661–674.
131.
JinCZhengYJinX, et al.Exposure-efficacy and safety analysis of durvalumab in patients with urothelial carcinoma (UC) and other solid tumors. J Clin Oncol2017; 35: 2568–2568.
132.
PalSKUzzoRKaramJA, et al.Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet2022; 400: 1103–1116.
133.
PowlesTDuránIVan der HeijdenMS, et al.Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet2018; 391: 748–757.
134.
GalskyMDArijaJÁABamiasA, et al.Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet2020; 395: 1547–1557.
135.
SweeneyCJGillessenSRathkopfD, et al.Abstract CT014: iMbassador250: a phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Res2020; 80: CT014–CT014.
136.
PetersSKimASolomonB, et al.IMpower030: phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo)+ chemotherapy. Ann Oncol2019; 30: ii30.
137.
RittmeyerABarlesiFWaterkampD, et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet2017; 389: 255–265.
138.
DisisMLTaylorMHKellyK, et al.Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol2019; 5: 393–401.
139.
ChoueiriTKMotzerRJRiniBI, et al.Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol2020; 31: 1030–1039.
140.
BangYJRuizEYVan CutsemE, et al.Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol2018; 29: 2052–2060.
141.
PowlesTParkSHVoogE, et al.Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol2020; 38: LBA1–LBA1.
142.
BarlesiFVansteenkisteJSpigelD, et al.Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol2018; 19: 1468–1479.
143.
ZhaoXSuryawanshiSHruskaM, et al.Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol2017; 28: 2002–2008.
144.
RobertCLongGVBradyB, et al.Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med2014; 372: 320–330.
145.
OvermanMJMcDermottRLeachJL, et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol2017; 18: 1182–1191.
146.
KawazoeAItahashiKYamamotoN, et al.TAS-116 (Pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: an open-label, dose-finding, and expansion phase ib trial (EPOC1704). Clin Cancer Res2021; 27: 6709–6715.
147.
SuzukiSKawakamiHMiikeT, et al.Complete remission of colon cancer with ipilimumab monotherapy. Intern Med2021; 60: 957–958.
148.
HaagGMSpringfeldCGrünB, et al.Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – the PICCASSO phase I trial. Eur J Cancer2022; 167: 112–122.
149.
AndrewsLPMarciscanoAEDrakeCG, et al.LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev2017; 276: 80–96.
150.
LeDTDiazLAKimTW, et al.Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer2023; 186: 185–195.
151.
DiazLAShiuK-KKimT-W, et al.Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol2022; 23: 659–670.
152.
EngCKimTWBendellJ, et al.Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol2019; 20: 849–861.
153.
AntoniottiCRossiniDPietrantonioF, et al.Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol2022; 23: 876–887.
154.
PowlesTNecchiADuranI, et al.TROPHU-U-01 cohort 5: evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC). J Clin Oncol2023; 41: TPS598–TPS598.
RibasAErogluZTrigo PerezJMM, et al.AMBER Parts 1c and 1e: a phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma. Am Soc Clin Oncol2022; 40: 9513–9513.
157.
KimHGridelliCKapurD, et al.P1. 11-01 cobolimab with Dostarlimab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC): COSTAR lung. J Thorac Oncol2022; 17: S109–S110.
FalchookGSRibasADavarD, et al.Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER). J Clin Oncol2022; 40: 2504–2504.
160.
MartinezMKimSSt JeanN, et al. Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer. Oncoimmunology2021; 10: 1873607. 20210120.
161.
BabarQSaeedAMurugappanS, et al.Promise of dostarlimab in cancer therapy: advancements and cross-talk considerations. Drug Discov Today2023; 28: 103577.
162.
CicalaCMMusacchioLScambiaG, et al.Dostarlimab: from preclinical investigation to drug approval and future directions. Hum Vaccin Immunother2023; 19: 2178220.
RamalingamSTharaERaoS, et al.1268P JASPER: efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol2020; 31: S819–S820.
166.
LiuJGaillardSHendricksonAW, et al. An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial. Gynecol Oncol2021; 162: S17–S18.
GabrailNYBessudoAHamiltonEP, et al.IOLite: multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer. J Clin Oncol2019; 37: 2560–2560.
170.
Medicine NUSNLo. Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042. https://clinicaltrials.gov/ct2/show/NCT03307785 (October 12, 2017).
171.
Medicine NUSNLo. Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042. https://clinicaltrials.gov/ct2/show/NCT03250832 (October 12, 2017).
172.
RamalingamSSTharaEAwadMM, et al.JASPER: phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Cancer2022; 128: 65–74.
173.
NIH MoLNUS. Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants. https://clinicaltrials.gov/ct2/show/NCT03308942 (October 13, 2017).
GayCMStewartCAFrumovitzM, et al.Abstract CT218: a phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas. Cancer Res2023; 83: CT218–CT218.
McWilliamsRRKasiPMFosterNR, et al.Trial in progress: phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer. J Clin Oncol2023; 41: TPS780–TPS780.
PassigliaFBironzoPRighiL, et al.A prospective phase II single-arm study of niraparib plus Dostarlimab in patients with advanced non–small-cell lung cancer and/or malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: rationale and study design. Clin Lung Cancer2021; 22: e63–e66.
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung). https://clinicaltrials.gov/ct2/show/NCT04655976 (December 7, 2020).
182.
Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33). https://clinicaltrials.gov/ct2/show/NCT04679064 (December 22, 2020).
183.
GranadosALOMarinisFMeyersO, et al.Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab. J Clin Oncol2023; 41: 9099–9099.
184.
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC). https://clinicaltrials.gov/ct2/show/NCT04581824 (October 9, 2020).
185.
KariveduVRiazMKMathewsM, et al.A phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma. J Clin Oncol2022; 40: TPS6105–TPS6105.
186.
ZamulkoOKariveduVRiazMK, et al.Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients. J Clin Oncol2023; 41: 6046–6046.
DozFJuan-RibellesAMoraJ, et al.Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study. J Clin Oncol2023; 41: 10040–10040.
189.
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors (SCOOP), https://clinicaltrials.gov/ct2/show/NCT04544995 (September 10, 2020).
ParikhARWeekesCDBlaszkowskyLS, et al.A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer. J Clin Oncol2022; 40: 564–564.
AcobaJDRhoYFukayaE. Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma. J Clin Oncol2023; 41: 580–580.
198.
NookaAKWeiselKvan de DonkNWCJ, et al.Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol2021; 17: 1987–2003.
199.
LonialSGrosickiSHusM, et al.Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study. J Clin Oncol2022; 40: 8019–8019.
200.
CallanderNSRibragVRichardsonPG, et al.DREAMM-5 Study: investigating the synergetic effects of belantamab mafodotin plus inducible T-cell co-stimulator agonist (aICOS) combination therapy in patients with relapsed/refractory multiple myeloma. Blood2021; 138: 97.
201.
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). https://clinicaltrials.gov/ct2/show/NCT04126200 (October 15, 2019).
202.
RichardsonPGNookaAQuachH, et al.Dreamm-5 platform trial: Belantamab Mafodotin (Belamaf) in combination with four different novel agents in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood2020; 136: –2.
203.
RandallLO'MalleyDMonkB, et al.883TiP MOONSTONE/GOG-3032: a phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib+ dostarlimab in patients with platinum-resistant ovarian cancer. Ann Oncol2020; 31: S646–S647.
204.
RandallLMO'MalleyDMMonkBJ, et al.MOONSTONE/GOG-3032: interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). J Clin Oncol2022; 40: 5573–5573.
205.
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE). https://clinicaltrials.gov/ct2/show/NCT03955471 (May 20, 2019).
206.
KäsmannLEzeCTaugnerJ, et al.Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol2020; 15: 167.
207.
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC). https://clinicaltrials.gov/ct2/show/NCT03739710 (November 14, 2018).
208.
Hardy-BessardA-CMooreKNMirzaMR, et al.ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC). J Clin Oncol2019; 37: TPS5600–TPS5600.
209.
Hardy-BessardA-CMooreKNMirzaMR, et al.ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). J Clin Oncol2020; 38: TPS6101–TPS6101.
210.
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). https://clinicaltrials.gov/ct2/show/NCT03602859 (July 27, 2018).
211.
MadariagaAGargSTchrakianN, et al.Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma. J Clin Oncol2021; 39: 5574–5574.
HansenABauerTMorenoV, et al.First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: preliminary results from INDUCE-1. Ann Oncol2018; 29: viii404.
HyltonNMBlumeJDBernreuterWK, et al.Locally advanced breast cancer: mR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology2012; 263: 663–672.
216.
EssermanLJBerryDACheangMCU, et al.Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat2012; 132: 1049–1062.
MirzaMRMortensenCEAvall-LundqvistE, et al.ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Am Soc Clin Oncol2015; 33: 5607.
219.
HopeJMChenJWainszelbaumM, et al.OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib+ bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy. Am Soc Clin Oncol2018; 36: 5606.
220.
ChappleCMartinez-GarciaRSelvaggiL, et al.A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol2005; 48: 464–470.
221.
HamidOBaxterDEastonR, et al.488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors. BMJ Specialist J2021; 9: A1054.
222.
Hardy-BessardA-CMooreKNMirzaMR, et al.ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042)+ niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC). Am Soc Clin Oncol2019; 9: A-518.
223.
Hardy-BessardA-CMooreKNMirzaMR, et al.ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). Am Soc Clin Oncol2019; 37: 560.
224.
ScottEIsakoffSJTaghianAG, et al.Abstract OT2-09-01: TBCRC-055: a phase II study of NirAparib, Dostarlimab, and radiotherapy in metastatic, PD-L1 negative or immunotherapy-refractory triple-negative breast cancer (NADiR) – NCT04837209. Cancer Res2023; 83: OT2-09-01-OT02-09-01.
